1-(2-Nitrophenoxy)-3-oxa-5-pentanol | 74145-36-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-Nitrophenoxy)-3-oxa-5-pentanol
• 英文别名: 2-[2-(2-nitrophenoxy)ethoxy]ethanol
• CAS: 74145-36-1
• 化学式: C₁₀H₁₃NO₅
• 分子量: 227.217
• InChiKey: ZIQYRXKZBQGUKC-UHFFFAOYSA-N

物化性质

• 沸点：
  394.6±27.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  84.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2-Nitrophenoxy)-3-oxa-5-pentanol 在 sodium ethanolate 作用下， 以 吡啶 为溶剂， 反应 4.0h， 生成 2-<5-(2-Nitrophenoxy)-3-oxapentyloxy>benzoesaeure-ethylester
  参考文献：
  名称：

  Sieger, Heinz; Voegtle, Fritz, Liebigs Annalen der Chemie, 1980, # 3, p. 425 - 440

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯乙氧基乙醇 、 硝苯酚 在 氢氧化钾 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 20.0h， 以45%的产率得到1-(2-Nitrophenoxy)-3-oxa-5-pentanol
  参考文献：
  名称：

  Sieger, Heinz; Voegtle, Fritz, Liebigs Annalen der Chemie, 1980, # 3, p. 425 - 440

  摘要：

  DOI：

文献信息

• Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors
  申请人：Atrin Pharmaceuticals LLC

  公开号：US20160102104A1

  公开（公告）日：2016-04-14

  A macrocyclic compound having the structure of Formula (A), wherein each of R 1 and R 2 is independently (i) a 5-6 membered monocyclic aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (ii) an 8-10 membered bicyclic aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Each R 1 and R 2 may independently be substituted by 0, 1, 2, 3, or 4 substituents. Z 1 represents a covalent bond, an atom, or a functional group comprising a grouping of atoms, wherein the grouping of atoms includes at least one heteroatom selected from the group consisting of N, O, P, and S. Also, Z 1 may represent (i) a 5-6 membered monocyclic aromatic ring containing 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (ii) an 8-10 membered bicyclic aromatic ring containing 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Z 2 represents a covalent bond, an atom, or a functional group comprising a grouping of atoms, wherein the grouping of atoms includes at least one heteroatom selected from the group consisting of N, O, P, and S. Variable v is an integer having a value of 1 or 0. T is a carbon atom, a nitrogen atom, a sulfur atom, or an oxygen atom. L is a linking group covalently bonded to T when v has a value of 1 or L is covalently bonded to R 1 when v has a value of 0. L is covalently bonded to Z 2 when Z 2 is an atom or a functional group comprising grouping of atoms and/or L is covalently bonded to R 2 when Z 2 is a covalent bond. Each of R 3 , R 4 and R 5 may be the same as or different from each other and each is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteraralkyl is optionally substituted by one or more suitable substituents.

  具有Formula (A)结构的大环化合物，其中R1和R2中的每一个独立地是(i) 包含0-4个从氮、氧或硫中独立选择的杂原子的5-6成员单环芳香环；或(ii) 包含0-6个从氮、氧或硫中独立选择的杂原子的8-10成员双环芳香环。每个R1和R2可以独立地被0、1、2、3或4个取代基取代。Z1代表共价键、原子或包含来自N、O、P和S组成的杂原子中至少一个的原子团的官能团，Z1也可以表示(i) 包含0-4个从氮、氧或硫中独立选择的杂原子的5-6成员单环芳香环；或(ii) 包含0-6个从氮、氧或硫中独立选择的杂原子的8-10成员双环芳香环。Z2代表共价键、原子或包含来自N、O、P和S组成的杂原子中至少一个的原子团的官能团，变量v是一个值为1或0的整数。T是碳原子、氮原子、硫原子或氧原子。当v的值为1时，L是与T共价键合的连接基，或当v的值为0时，L与R1共价键合。当Z2是原子或包含原子团的官能团时，L与Z2共价键合，和/或当Z2是共价键时，L与R2共价键合。R3、R4和R5中的每一个可以相同也可以不同，每个独立地从氢、烷基、烯基、炔基、环烷基、环烯基、杂环烷基、芳基、杂芳基、芳基烷基和杂芳基中选择，其中每个烷基、烯基、炔基、环烷基、环烯基、杂环烷基、芳基、杂芳基、芳基烷基和杂芳基可以选择性地被一个或多个适当的取代基取代。
• Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
  申请人：Atrin Pharmaceuticals LLC

  公开号：US10196405B2

  公开（公告）日：2019-02-05

  Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided: wherein R1, R2, R3, R4 and R5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

  提供了具有式（A）结构的大环化合物或其药学上可接受的盐类： 其中 R1、R2、R3、R4 和 R5 在本文中定义。还提供了包含大环化合物的药物组合物和治疗患者癌症的方法，包括给患者施用大环化合物。
• Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists
  作者：Aiko Nitta、Yosuke Iura、Hideki Inoue、Ippei Sato、Koichiro Morihira、Hirokazu Kubota、Tatsuaki Morokata、Makoto Takeuchi、Mitsuaki Ohta、Shin-ichi Tsukamoto、Takayuki Imaoka、Toshiya Takahashi

  DOI：10.1016/j.bmcl.2012.09.035

  日期：2012.11

  Optimization starting with our lead compound 1 (IC50 = 4.9 nM) led to the identification of pyrrolidinyl phenylurea derivatives. Further modification toward improvement of the bioavailability provided (R)-1-(1-((6-fluoronaphthalen-2-yl)methyl)pyrrolidin-3-yl)-3-(2-(2-hydroxyethoxy)phenyl)urea 32 (IC50 = 1.7 nM), a potent and orally active CCR3 antagonist. (C) 2012 Elsevier Ltd. All rights reserved.
• SIEGER H.; VOEGTLE F., LIEBIGS ANN. CHEM., 1980, NO 3, 425-440
  作者：SIEGER H.、 VOEGTLE F.

  DOI：——

  日期：——
• ATAXIA TELENGIECTASIA AND RAD3-RELATED (ATR) PROTEIN KINASE INHIBITORS
  申请人：Atrin Pharmaceuticals LLC

  公开号：EP3207031B1

  公开（公告）日：2021-04-14